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Background In a population-based study, we examined the
relationship between the risk of myocardial infarction (MI)
among young women and plasma total homocysteine (tHCY),
folate, vitamin B12, and a common cytosine (C) to thymine (T)
polymorphism in the gene for 5,10-methylenetetrahydrofolate
reductase (MTHFR).
Methods and Results In-person Interviews and nonfasting
blood samples were obtained from 79 women <45 years old
diagnosed with MI and 386 demographically similar control
subjects living in western Washington state between 1991 and
1995. Compared with control subjects, case patients had higher
mean tHCY concentrations (13.4±5.2 versus 11.1 ±4.4 μιηοΙ/L,
ί"=.0004) and lower mean folate concentrations (12.4±13.4 ver-
sus 16.1+12.2 nmol/L, P=.018). There was no difference in
vitamin B12 concentrations between case patients and control
subjects (346.8±188.4 versus 349.7+132.4 pmol/L, P=.90). After
adjusting for cardiovascular risk factors, we found that women
with tHCY 2=15.6 μπιοΙ/L were at approximately twice the risk of
Homocysteine is a thiol-containing metabolite ofmethionine with atherogenic and thromboticproperties.1 Studies conducted primarily
among young to middle-aged men indicate that mildly
elevated blood levels of tHCY—the sum of protein-
bound or free forms of homocysteine and its disulfides,
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MI äs women with tHCY <10.0 μιηοΙ/L (OR, 2.3; 95% CI, 0.94
to 5.64). Women with folate >8.39 nmol/L had an «50% lower
risk of MI than women with folate <5.27 nmol/L (OR, 0.54; 95%
CI, 0.23 to 1.28). There was no association with vitamin B„2
concentration. Among control subjects, 12.7% were homozygous
for the MTHFR T*77 allele, and these women had higher plasma
tHCY and lower plasma folate than women with other genotypes.
Ten percent of case patients were homozygous for
te T677 allele, and there was no association of homozygosity
for T677 with MI risk (OR, 0.90; 95% CI, 0.31 to 2.29).
Conclusions These data support the hypothesis that ele-
vated plasma tHCY and low plasma folate are risk factors for
MI among young women. Although homozygosity for MTHFR
T677 is related to increased plasma tHCY and low plasma
folate, this genetic characteristic is not a risk factor for MI in
this population. (Circulation. 1997;96:412-417.)
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homocysteine and cysteine-homocysteine—are a risk
factor for CHD, stroke, and possibly other forms of
arterial and venous vascular disease.2 Low blood levels
of folate appear to be a particularly strong environmen-
tal determinant of tHCY levels in many populations.2
Genetic factors also contribute to tHCY levels, and
recent studies have focused on a common inherited
Variation in the enzyme MTHFR. MTHFR catalyzes the
reduction of 5,10-methylenetetrahydrofolate to 5-meth-
yltetrahydrofolate, a reaction that contributes Substrates
for the remethylation of homocysteine to methionine by
methionine synthase. Kang et al3-5 reported that up to
5% of the population has an inherited thermolabile form
of MTHFR, one that is associated with reduced enzyme
activity and premature CHD. Thermolabile MTHFR
reportedly accounts for =»25% to 30% of elevated tHCY
in patients with premature vascular disease.6 A common
single-base-pair change, cytosine (C) to thymine (T), at
nucleotide 677 of the MTHFR gene was recently iden-
tified,7 and persons homozygous for the T allele were
more likely to have thermolabile MTHFR and elevated
tHCY than persons with other genotypes. Thus, the
C677->r polymorphism in the MTHFR gene may be a
genetic risk factor for premature cardiovascular
disease.7·8
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Selected Abbreviations and Acronyms
CHD = coronary heart disease
CI = confldence interval
MI = myocardial infarction
MTHFR = 5,10-methylenetetrahydrofolate reductase
OR = odds ratio
tHCY = total homocysteine
Although the strong inverse correlation between fo-
late and tHCY Supports the hypothesis that reduced
folate Status may be a risk factor for CHD, those few
studies that examined this relationship have yielded
conflicting results.9-14 Similarly, while some investiga-
tions have found the risk of vascular disease to be
increased among persons homozygous for the MTHFR
T677 allele,15-17 others have not.18-20 We studied the
relationship of plasma tHCY, plasma folate, and the
MTHFR C6?7->T polymorphism to the risk of acute MI
among young women in a population-based case-control
study.
Methode
Subjects
The data for this report were drawn from a study of incident
cardiovascular disease (MI and stroke) among women 18 to 44
years old residing in King, Pierce, and Snohomish counties,
Washington state. Eligible MI case patients were women
diagnosed with a first fatal or nonfatal MI between July l, 1991,
and February 28,1995, who had no prior history of major CHD
or stroke. We identified potential case patients through
monthly review and abstraction of discharge diagnoses of acute
ischemic heart disease provided by all hospitals within the study
region, incident reports from emergency medical Service Sys-
tems, and death certificates listing out-of-hospital deaths from
cardiovascular disease and related conditions. We identified
208 eligible MI patients with definite or probable MI on the
basis of the criteria used by the Cardiovascular Health Study,21
of whom 161 were living at the time that we initiated recruit-
ment. We recruited 107 of these women into the study, 4 were
not approached at the request of their physicians, and the
remainder either refused to participate (n=40) or could not be
located (n=10).
We used random-digit telephone dialing to identify a sample
of women 18 to 44 years old who were residents of King, Pierce,
or Snohomish counties during the case diagnosis period.
Briefly, telephone numbers were generated at random with a
Computer algorithm, and a household census to ascertain
women meeting the eligibility criteria was completed for 94.9%
of the residences contacted. Among the eligible women iden-
tified, we attempted to enroll 691 at random, frequency
matched to the combined age distribution of all cardiovascular
disease patients recruited for the study. Only l woman from
each household was selected for recruitment. Seven of the 691
women were excluded because of a prior history of major
cardiovascular disease (n=6) or inability to communicate in
English (n=l). Of the remaining 684 women, 526 were re-
cruited into the study, for an estimated overall response rate of
72.8% (94.9% of 526/684).
Data Collection
Participating case patients and control subjects were inter-
viewed in person regarding histories of known or suspected
cardiovascular risk factors, including histories of physician-
diagnosed diabetes, hypertension, or high cholesterol; cigarette
Smoking; height and weight; menstrual history; contraceptive
practices; alcohol consumption; physical activity; history of MI
in first-degree relatives; and demographic characteristics. No
Information was collected on dietary or nutritional Supplement
sources of vitamins. The structured interview elicited Informa-
tion only from the time period before the MI in each case
patient. Hence, in this report we use the term "current" to
describe characteristics of each patient äs of the date that she
had her MI (or equivalent date for control subjects). In
addition to the in-person interview, we also obtained a 30-mL
venous blood specimen from 79 MI case patients and 391
control subjects into EDTA-treated vacuum tubes; aliquots of
plasma and buffy coat were frozen at — 70°C. Case blood
samples were obtained at least 3 months after the event (mean,
8 months; median, 6.5 months).
Laboratory Analyses
Plasma tHCY concentrations were determined by high-
pressure liquid chromatography and electrochemical detection
äs previously described.22 Plasma folate and vitamin B12 con-
centrations were measured with the Quantaphase II Assay
System (Bio-Rad Laboratories). Genomic DNA was extracted
from buffy-coat aliquots by established methods.23 The C677-^T
Variation in the MTHFR gene was determined äs described by
Frosst et al.7 tHCY measurements were available for 79 case
patients and 386 control subjects, folate and vitamin B12
measurements were available for 77 case patients and 382
control subjects, and MTHFR genotyping for 79 case patients
and 379 control subjects. We also measured HDL cholesterol,
LDL cholesterol, and triglycerides, by Standard methods, on a
subset of case patients (n=63) and control subjects (n=140)
selected at random.24 All laboratory analyses were conducted
blind äs to whether a sample came from a case patient or
control subject.
Statistical Analysis
For initial analyses of the relationship between MI risk and
concentrations of tHCY, folate, and vitamin B12, we compared
case patients and control subjects with respect to the mean
concentrations of these compounds. The distributions of folate
and vitamin B12 were skewed, but because case-control com-
parisons of geometric means and arithmetic means yielded
identical results, only the latter are presented. For the risk of
MI associated with tHCY, folate, and vitamin B12, we classified
the data into approximate quartiles based on the distribution of
these compounds among case patients. We then used uncon-
ditional logistic regression models to estimate ORs and 95%
CIs for each quartile.25 For each of these compounds, we
investigated potential confounding by age (in years); education
(less than College, College, postcollege); ethnicity (non-Hispan-
ic white, black, other); cigarette smoking (current, past, never);
obesity (body mass index >27.3 kg/m2 versus <27.3 kg/m2);
currently receiving medical treatment for hypertension, diabe-
tes, or high cholesterol; menopausal Status (postmenopausal
versus premenopausal); average frequency of alcohol use in the
previous year (three or more times per week, less than three
per week, none); average frequency of vigorous exercise in the
previous year (once per week, less than once per week, never);
and current use of oral contraceptives (yes, no). Potential
confounding by plasma lipid measures was investigated within
the subset of case patients and control subjects with data
available on those characteristics. Except for age, terms for
confounders were retained in the model if they produced an
important change in the coefficient for a particular plasma
measurement. To evaluate the extent to which the pattern of
ORs for tHCY, folate, or vitamin B12 were consistent with a
linear trend in risk, we computed the difference in the log-
likelihoods between hierarchical models containing three indi-
cator terms and models containing a single term with four
levels (0, l, 2, 3) corresponding to each quartile. In this
approach, the smaller the diiference in log-likelihoods, the
strenger the evidence that the patterns of ORs are consistent
with a linear trend. We also examined the extent to which
associations with tHCY, folate, and vitamin Bt2 varied by
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TABUE 1. Distribution of Demographic Characteristics
and Cardiovascular Risk Factors Among MI Case and
Control Subjects
Charactenstic
Age, y
18-29
30-34
35-39
40-44
Ethnicity
Whrte, not Hispanic
Black
Other
Education
Less than College
College
Postcollege
Cigarette Smoking
Current
Past
Never
Currently receivmg treatment for
Hypertension
Diabetes
High cholesterol
Body mass mdex £27 3 kg/m2
Postmenopausal
Current oral contraceptive use
First-degree relative with history of MI
Frequency of vigorous exercise*
a3 times/wk
Some but <3 times/wk
None
Frequency of alcohol consumption*
ä1 time/wk
Some but <1/wk
None
Case
Patients
(n=79)
1 3
127
228
633
873
63
63
582
354
63
696
165
139
165
63
25
582
329
51
544
77
231
692
324
494
182
Control
Subjects
(n=386)
80
132
321
466
891
23
86
275
557
168
21 1
237
552
23
05
05
272
11 1
106
298
242
398
359
387
395
21 8
Values are percent Percents may not add up to 100 because of
roundmg
*Average over year before diagnosis or reference date
whether a woman was a current cigarette smoker, obese, or had
a first-degree relative with a history of MI, these charactenstics
were the only established cardiovascular nsk factors for which
we had sufficient numbers of case patients and control subjects
to mvesügate heterogeneity m nsk Likelihood ratio tests were
used to estimate the extent to which chance might account for
any differences we observed in associations between analytes
and MI nsk according to smokmg, obesity, or famdy history
Status
We exammed the distnbution of MTHFR genotypes among
control subjects and the relationship of genotype to tHCY,
folate, and vitamm B12 concentrations ORs for the association
of homozygous T677 and heterozygous T677 genotypes, com-
pared with homozygous C genotypes, were estimated by the
Mantel-Haenszel method All analyses of MTHFR genotypes
were restncted to non-Hispanic whites to reduce the influence
of genetic heterogeneity on our results
Results
The study populaüon was largely white, not of His-
panic ongm, but blacks were overrepresented among the
case patients (Table 1). Case patients were much more
hkely than control subjects to be currently receivmg
medications for hypertension, diabetes, or high choles-
terol; to be postmenopausal; and to have a first-degree
relative with a history of MI. Cigarette smokmg, obesity,
and family history of MI were extremely comnion among
case patients. »»70%, 60%, and 54% of the patients
reported these charactenstics, respectively, compared
with «21%, 27%, and 30% of control subjects. Case
patients also tended to have less formal education and
were less hkely to be current users of oral contraceptives
and to participate m regulär vigorous physical activity
than control subjects
Compared with control subjects, case patients had
higher mean tHCY concentrations (13.4±5.2 versus
11.1±4.4 jumol/L, F=.0004) and lower mean folate
concentrations (12.4±13.4 versus 16.1±12.2 nmol/L,
F=.018) There was no difference in vitamm Bi2 concen-
trations between case patients and control subjects
(3468±188.4 versus 349.7±132.4 pmol/L, P=.90).
Among control subjects, tHCY concentrations were
mversely associated with concentrations of folate after
adjustment for vitamm B12 (/-=-.397, F=.0001), whereas
vitamm B12 concentrations were not related to tHCY
after adjustment for folate (r=-.082, P=.ll).
The nsk of MI adjusted for age, diabetes, cigarette
smokmg, and obesity among young women mcreased
with increasing quartile of tHCY and decreased with
mcreasmg quartile of folate (Table 2), the patterns of
TABLE 2. Adjusted Risk of MI Among Young Women Associated With Quartiles of
tHCY, Folate, and Vitamin B12 Concentrations
Quartile
Plasma Measure
tHCY, ^mol/L
No cases No controls
Range/median
OR (95% Cl)*
Folate, nmol/L
No cases No controls
Range/median
OR (95% Cl)"
B12, pmol/L
No cases No controls
Range/median
OR (95% Cl)*
l
19187
4 05 9 99/8 23
1 00
1940
1 90-5 26/4 43
1 00
1975
67-229/181
1 0
II
20106
1000-1259/11 17
1 34 (0 63, 2 82)
1976
5 27-8 38/6 65
0 72 (0 29, 1 71)
1992
230-311/289
092 (038,22)
III
21 57
1260-1559/1391
1 98 (0 89, 4 43)
19100
839-1392/983
047 (020, 1 12)
1972
312-384/342
1 23 (0 50, 3 0)
IV
1936
1560 6585/21 18
230 (094,564)
20166
1393-8280/1978
0 54 (0 23, 1 28)
20142
385-1492/504
0 66 (0 29, 1 56)
'Adjusted for age (contmuous), cigarette smokmg (current, former, never), currently taking medicine for
diabetes, and body mass mdex (<27 3 kg/ma vs s27 3 kg/m2)
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risk for both tHCY and folate were consistent with a
monotonic trend based on likelihood ratio tests (tHCY,
X22df =0.401, P=.818; folate, ^  =1.68, P=.432). When
adjusted for tHCY, the association with folate was
weakened; the ORs for folate of a 13.93 nmoI/L, 8.39 to
13.92 nmol/L, and 5.27 to 8.38 nmol/L were 0.76 (95%
CI, 0.29 to 1.96), 0.56 (95% CI, 0.23 to 1.38), and 0.79
(95% CI, 0.32 to 1.96), respectively. There was little
relationship between vitamin B12 concentration and MI
risk. These results were essentially unchanged when we
adjusted for menopausal Status, race, treated hyperten-
sion, treated high cholesterol, exercise, alcohol con-
sumption, or oral contraceptive use. Furthermore,
among the women for whom we had measures of plasma
lipid concentrations, controlling for these measures did
not alter the relationships with tHCY, folate, or vitamin
B12. The results also did not diifer after exclusion of the
few women who were being treated for hypertension or
were taking oral contraceptive puls. We also conducted
analyses in which we (1) excluded the 20% of case
patients for whom the blood draw was performed rela-
tively close to the event (3 to 4 months) or relatively
distant from the event (>14 months) and (2) estimated
associations separately for case patients with blood
drawn within 6.5 months of the event and for case
patients with blood drawn after this interval; these
analyses resulted in trivial changes in the associations.
The ORs for eleväted tHCY (s!2.6 μπιοΙ/L) among
smokers (55 case patients and 83 control subjects) and
nonsmokers (24 case patients and 303 control subjects)
were similar: 1.92 (95% CI, 0.91 to 4.96) and 1.86 (95% CI,
0.66 to 5.22) (heterogeneity, x2Uf =0.059, P=.808), äs were
the ORs among women with (43 case patients and 112
control subjects) and without (34 case patients and 266
control subjects) a family history of MI: 2.07 (95% CI, 0.89
to 4.82) and 2.07 (95% CI, 0.91 to 4.73) (heterogeneity,
Χ
2
ω/=0·000, Ρ=.999). Among obese women (46 case pa-
tients and 104 control subjects), there was no association
with tHCY >12.6 μηιοΙ/L (OR, 1.14; 95% CI, 0.48 to 2.71),
whereas among nonobese women (33 case patients and 279
control subjects), the OR was eleväted (OR, 3.20; 95% CI,
1.35 to 7.57) (heterogeneity, χ%·=4.451, f>=.035). The
ORs for eleväted folate (a8.39 nmol/L) did not vary
according to whether or not the woman smoked, was
obese, or had a family history of MI.
About one eighth (12.7%) of the 338 non-Hispanic
white control subjects were homozygous and 41.7% were
heterozygous for the MTHFR T677 allele (Table 3).
Folate concentrations were 30% lower and tHCY con-
centrations were 25% higher among women homozy-
gous for MTHFR T677 compared with women possessing
at least one copy of the C677 allele. The excess tHCY
concentration among MTHFR T677 homozygotes was
present only among women with low plasma folate
(<8.39 nmol/L). Among all non-Hispanic white control
subjects, 30% of women with tHCY >15.6 μιηοΙ/L (the
90th percentile among control subjects), compared with
10% of women with tHCY below this level, were ho-
niO2ygous for MTHFR T677. Among the non-Hispanic
white MI case patients, MTHFR T677 homozygotes had
tHCY levels that were similar to other case patients
(mean±SD, 13.2±6.9 versus 13.4±4.9 μηιοΙ/L, respec-
tively) but had lower folate levels (mean±SD, 10.3±5.9
versus 13.0±14.8 μιηοΙ/L, respectively).
TABLE 3. Plasma Folate and tHCY Concentrations
Among Control Subjects* by MTHFR C/T677 Genotype
Genotype
Plasma Measurement CC(n=154) CT(n=141) 7T(n=43)
Folate, nmol/L
tHCY, μηηοΙ/L
By folate concentration,
nmol/L
16.43(11.81) 16.36t (13.02) 11.08t (9.56)
10.85(3.79) 10.76t (3.91) 13.48t (7.00)
cc+cr
<8.39(n=100)
8.39-1 5.59 (n =108)
>15.60 (n =109)
12.71 (4.50)
11.45(4.13)
9.18(2.50)
18.12§(8.36)
10.96§(2.41)
7.35§ (2.05)
Values are mean (SD) plasma concentration.
*Restricted to non-Hispanic whites.
tCompared with CC genotype, P=.95 for i test on difference in mean
folate and P=.70 for f test on difference in mean tHCY.
tCompared with CC genotype, P=,02 for i test on difference in mean
folate and P=.02 for f test on difference in mean tHCY.
§Compared with CC and CTgenotypes combined, P=.013 for folate
<8.39 nmol/L, P=.513 for folate 8.39-15.59 nmol/L, P=.063 for folate
>:15.60 nmol/L.
The distribution of MTHFR C677-*T genotype was
similar among non-Hispanic white case patients and
control subjects, and the risk of MI was not associated
with homozygosity or heterozygosity for the T677 allele
(Table 4). This result was unchanged when we excluded
the women who reported currently receiving medication
for hypertension, diabetes, or high cholesterol. No asso-
ciation was observed after the population was stratified
according to plasma folate level (data not shown).
Discussion
We observed an increasing risk of MI among young
women with increasing plasma tHCY concentration,
and in particular an approximately twofold increased
risk for women with plasma tHCY concentrations of
>15.6 μιηοΙ/L (the 90th percentile of the distribution
among control subjects in our study). This association
is consistent with the accumulated evidence support-
ing tHCY äs a risk factor for CHD but is somewhat
weaker than has been observed in the few, relatively
small previous studies that presented results for wom-
en 11,12,26,27 important features of these earlier studies
that differ from the present report are the inclusion of
(1) older women (predominantly or entirely post-
menopausal),12·26 (2) case patients (but not control
subjects) required to have a strong family history of
CHD,27 and (3) patients who have CHD but not
necessarily MI.11·12·26·27 That traditional risk factors
such äs cigarette Smoking and obesity appear to
account for the great majority of MI case patients in
very young women could also contribute to our finding
a weaker association between MI and tHCY than
might be predicted from previous studies. Regarding
the possible modifying role of these important estab-
TABLE 4. Risk of MI Among Young Women* According
to MTHFR C/T677 Genotype
Genotype
CC
er
7T
Case Patients
28 (40.6)
34 (49.3)
7(10.1)
Control Subjects
154(45.6)
141 (41.7)
43(12.7)
OR (95% CI)
1.00
1.33(0.74,2.39)
0.90(0.31,2.29)
Values are No. of women (%).
*Restricted to non-Hispanic whites.
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lished risk factors, neither of the two previous studies
of tHCY and CHD that investigated whether the
relationship varies among persons with and without
other CHD risk factors reported results by obesity,13·28
whereas Verhoef et al13 found no Variation by smoking
Status.
The «50% reduction in risk we observed with folate
concentrations &S.39 nmol/L (the 30th percentile of the
distribution among control subjects) is consistent with
most previous studies,9·10·13·14 but other investigations
have not observed any relationship between plasma
folate and CHD.11·12 The absence of a relationship
between plasma folate and CHD in some previous
studies11·12 may reflect differences among populations in
the importance of other vitamin determinants of tHCY
concentrations, such äs pyridoxal-5'-phosphate. It is
possible that our fmdings are to some extent confounded
by unmeasured nutritional factors (eg, vitamin E) that
may influence CHD risk through other mechanisms.
However, adjustment of folate for tHCY weakened the
inverse relationship with folate, suggesting that the effect
of folate on tHCY levels is responsible for the observed
trend in risk with folate levels. We did not observe any
difference in vitamin B12 concentrations between case
patients and control subjects, consistent with most pre-
vious reports.9·11-13
Our findings for tHCY, folate, or vitamin Bn may not
reflect the relationships with MI that would be observed
had we used a prospective study design, but such an
approach is not feasible given the extremely infrequent
occurrence of MI in young women. We did not attempt
to measure whether or how the diets of MI patients had
changed after their events. If diets of patients improved
and included higher intake of folate, our results would
represent underestimates of the true associations. Alter-
natively, if the diets of patients included less folate than
before the MI, our results might overestimate the true
associations. Given the generally good agreement be-
tween results of previous prospective and retrospective
studies of tHCY and CHD, it seems unlikely that the
associations we observed are very different from those
that we would have found had measurements been
obtained before the ML Our participation rates were
relatively low, but our results would be biased only to the
extent that case patients and control subjects would
differ with respect to the association between participa-
tion and plasma tHCY, folate, and vitamin Bi2 concen-
trations. Among the women we interviewed, we did not
identify any differences in demographic characteristics
or cardiovascular risk factors between the women who
did and did not provide a blood sample (data not
shown). Finally, elevated tHCY could be part of the
causal path through which smoking, diabetes, and obe-
sity exert their respective causal effects on MI, and thus
we may have underestimated the association with tHCY
when we included these characteristics in our logistic
models. However, there are other, more firmly estab-
lished mechanisms through which smoking, diabetes,
and obesity affect MI risk. In addition, inclusion of
tHCY in the logistic regression models caused minimal
change in the coefficients for these factors (data not
shown), making it unlikely that elevated tHCY mediales
more than a very small proportion of the effect of
smoking, diabetes, and obesity on MI risk in our popu-
lation. Hence, adjustment for smoking, diabetes, and
obesity was necessary to avoid overestimating the inde-
pendent association between tHCY and MI in young
women.
Consistent with previous investigations in other pop-
ulations,7·15·20'29·30 we observed that young women in the
general population carrying two copies of the MTHFR
T677 allele had nonfasting plasma tHCY concentrations
that were «25% higher than women with other geno-
types. In addition, we found, äs have others,20·29 that the
difference in plasma tHCY concentrations between
MTHFR T677 homozygotes and persons with other geno-
types is limited to individuals with low plasma folate
levels. One previous study also reported that this pattern
held when persons were classified according to use of
multivitamins,20 providing evidence that the MTHFR
C677-^T polymorphism and folate intake interact to
cause elevated tHCY. Randomized feeding studies,
however, would be the strengest design to test the
hypothesis that the relationship between folate intake
and tHCY is modified by an individual's MTHFR C677/T
genotype.
Although homozygosity for the MTHFR T677 allele
was significantly associated with increased plasma tHCY
in our population, we did not observe an increased risk
of MI among women possessing this genotype. Three
recent studies also did not find an association between
the MTHFR polymorphism and CHD,18-20 in contrast to
three studies that have reported twofold to threefold
increased risks of CHD or other vascular disease among
those carrying two copies of the T677 allele.15-17 The
seven reports to date have examined different manifes-
tations of vascular disease and different sexes and ages of
patients, and varied considerably in size, yet these design
features do not clearly distinguish studies that have
observed an association from those that have not. Posi-
tive and negative studies also do not appear to differ
consistently in the contribution of MTHFR T677 to
elevated tHCY: 40% and 16% of subjects with elevated
tHCY carried two copies of the MTHFR T677 allele in the
Danish15 and Irish17 studies, respectively, compared with
21% and 30% in the Physicians Health Study20 and our
study, respectively. If the association between the
MTHFR polymorphism and elevated tHCY depends on
the amount of 5,10-methylenetetrahydrofolate available
to the enzyme, it may be that an association between the
homozygous T677 genotype will be observed only among
persons with low folate intake. Two studies that reported
no overall association with homozygosity for MTHFR
T677 also did not find compelling evidence of an associ-
ation among persons with low folate intake,19·20 but the
sample sizes were limited. Populations also may differ in
the extent to which homozygosity for MTHFR T677 is
associated with the thermolabile MTHFR phenotype. In
that regard, it is interesting to note that those studies
that observed an association were conducted in popula-
tions that potentially are rnore genetically homoge-
neous15'17 than those studies (including ours) that failed
to find an association.18-20 Finally, given that clinical
trials have not been conducted to determine whether
lowering tHCY levels can reduce cardiovascular disease
occurrence, the causal role of this risk factor has not
been fully established. If tHCY in fact is not causally
related to cardiovascular disease, then no association
would be expected between MI risk and the C677-^T
polymorphism in the MTHFR gene.
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The growmg evidence supporting a role for low folate
m the occurrence of cardiovascular disease is likely to
lead to randomized tnals to provide definitive tests of
this hypothesis31 Whether mdividuals who carry two
copies of the MTHFR T677 allele are particularly suscep-
tible to the putative adverse cardiovascular effects of low
folate is still unclear Thus, randomized tnals should be
complemented by additional expenmental and observa-
tional studies designed to clanfy the role of this genetic
charactenstic and other potential mhented mfluences on
folate metabohsm m the association between folate,
tHCY, and cardiovascular disease nsk
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